Hematologic Diseases  >>  delanzomib (CEP-18770)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
delanzomib (CEP-18770) / Teva
NCT01023880 / 2009-013778-41: Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Terminated
1/2
62
US
CEP-18770, delanzomib
Cephalon
Multiple Myeloma
11/12
01/13
NCT01348919: Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Completed
1/2
11
US, RoW
CEP-18770, Delanzomib, Lenalidomide, Dexamethasone
Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Myeloma
03/13
03/13

Download Options